By Fineline Cube 
Johnson & Johnson (NYSE: JNJ) announced on July 22, 2026 that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, establishing the world’s first table-integrated soft tissue robotic platform. The system received marketing authorization for ten general surgery procedures, marking Johnson & Johnson’s strategic entry into the surgical robotics market with a fundamentally reimagined architectural approach.
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Company | Johnson & Johnson (NYSE: JNJ) |
| Regulatory Pathway | FDA De Novo authorization (novel device without predicate) |
| Approval Date | 22 Jul 2026 |
| Device | OTTAVA™ Robotic Surgical System |
| Classification | World’s first table-integrated soft tissue robotic system |
| Authorized Indications | 10 general surgery procedures |
Authorized Surgical Procedures
The OTTAVA system is cleared for the following general surgery indications:
- Roux-en-Y gastric bypass
- Gastrectomy
- Cholecystectomy
- Splenectomy
- Gastric sleeve
- Small bowel resection
- Appendectomy
- Lysis of adhesions
- Fundoplication
- Hiatal hernia repair
Additional indications under development, including ongoing U.S. clinical trial for inguinal hernia procedures
System Architecture & Innovation
Space-Efficient Design
- Smallest multi-port soft-tissue robotic footprint: Integrates robotic arms directly into OR table
- 30–50% less space than traditional boom- and cart-mounted systems
- Enhanced surgeon and clinical team mobility with improved communication pathways
Automation & Workflow Enhancement
- Four table-integrated arms with sophisticated software coordination
- Automated, pre-defined procedural poses simplify setup and breakdown
- Twin motion technology: Synchronized table and arm movement enables seamless patient repositioning and multi-quadrant anatomical access
Purpose-Built Instrumentation
- Two-in-one needle driver: Reduces unintended suture cutting
- Monopolar curved scissors: Ensures consistent and complete tissue cuts
- Portfolio reimagined based on generations of open and laparoscopic surgical experience
Digital Ecosystem Integration
- Polyphonic™ for OTTAVA™: Secure digital solution integrating learning, media, and data-driven insights
- Supports continuous improvement across the surgical journey
- Foundation for future digitally enabled, data-driven surgery
Commercial Strategy & Market Impact
- Phased Launch: Initial commercial rollout with select U.S. customers focused on early success validation
- Global Expansion: Parallel development for additional indications and international regulatory jurisdictions
- Market Entry: Strategic positioning in the $8.5 billion global surgical robotics market
- Competitive Differentiation: Addresses key adoption barriers including space constraints, workflow complexity, and total cost of ownership
Executive Perspective
“We are pioneering a new category of surgical robotics with OTTAVA,” said Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson. “This is the start of the next era in surgery as we deliver not just a new surgical robotics system, but a catalyst for fundamentally better surgical care.”
“Surgical robotics will play an increasingly important role in surgical care, but it’s clear that what defined the last 25 years of surgery will not define the next 25,” added Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson.
Clinical Support & Education
- Comprehensive Training Program: Virtual, hands-on, and immersive training developed with clinicians and surgical societies
- Legacy Backing: Supported by Johnson & Johnson’s established continuous education infrastructure
- Safe Adoption Framework: Designed to ensure consistent performance for both new and experienced robotic surgeons
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial launches, clinical trials, and market opportunities. Actual results may differ due to risks including commercial implementation timelines, regulatory requirements in other jurisdictions, competitive dynamics, and clinical trial outcomes.